EUCTR2008-005075-10-FI进行中（未招募）不适用
Double-blind, vehicle-controlled, two-phase, single centre Phase I/IIa study with topical twice daily doses of 5% cis-urocanic acid to investigate pharmacokinetics, safety, tolerability and efficacy for up to 28 days in subjects with mild to moderate atopic dermatitis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Informed consent obtained prior to any screening procedures
- •2. White skinned male or female subjects
- •3. Age between 18-65 years of age
- •4. Subjects with chronic mild to moderate atopic dermatitis with the following diagnostic features:
- •- History within 12 months of itching dermatitis in one or several of localizations typical of atopic dermatitis (antecubital/cubital fossae; face/neck/upper trunk; volar aspects upper extremities / thighs).
- •- Objective signs of mild or moderate eczema OR dry skin in one or several of above mentioned locations
- •5. No current treatment with active medication for atopic dermatitis
- •6. Symmetric presentation of atopic dermatitis in the volar forearms to allow randomization of the treatments
- •7. Good general health ascertained by medical history, physical examination, ECG-recording and laboratory determinations, showing no signs of clinically significant findings, except chronic atopic dermatitis
- •8. Negative pregnancy test (premenopausal female subjects) at screening and use of adequate contraceptive measures (both male and female subjects) throughout the study and 30 days after the last cis-UCA dose
- •- Premenopausal female volunteers should be either surgically sterile or using a reliable contraception method: intrauterine device (hormonal or non-hormonal); oral combination pill or hormonal contraception patch; or two of the following: intra-vaginal hormonal ring, oral contraceptive containing progestin only, spermicidal foam, condom, sterilization of male sexual partner (surgical vasectomy)
- •- Subjects with no current heterosexual relationship may be included according to the judgment of the Investigator
- •- If menopause occurred 2 years ago at the minimum, no contraception is required for female participants, nor pregnancy tests
- •- Reliable contraception for male subjects is concordant with above listed methods for females, as applicable
- •9. Body weight 60-100 kg for males and 45 -85 kg for females; body mass index (BMI) 18-30 kg/m2
- •10. Supine blood pressure (BP) after 3 minutes rest: systolic 100-150 mmHg, diastolic 60-90 mmHg, and supine heart rate (HR) after at least 3 minutes rest: 40-90 beats per minute
- •11. Non-smoker and not using any nicotine products
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. History of other significant skin disease (e.g. any skin disease requiring hospitalization), or skin manifestations of allergic illness or other dermatologic condition, except chronic mild to moderate atopic dermatitis, that would interfere with the trial assessments or compromise the subject’s safety according to the opinion of the Investigator
- •2. Present symptoms of other skin diseases, except chronic atopic dermatitis, that could disturb the study assessment and evaluation of the skin, according to the opinion of the Investigator
- •3. Current use of any active systemic medication (i.e. oral, subcutaneous, intravenous) for chronic atopic dermatis within one month (30 days)
- •4. Current use of active topical medication in the investigational area for chronic atopic dermatis within one month (30 days)
- •5. History of a sunny holiday or solarium use within one month (30 days) before beginning of study treatments, or planning such during the study or within 30 days after the study
- •6. Asymmetric presentation or only single lesion of atopic dermatitis on volar forearms
- •7. Tattoos on the volar side of either forearm
- •8. Damaged skin at the test site (e.g. uneven skin pigmentation, numerous freckles, scars or other disfigurations) or clinical signs or symptoms of skin irritation (e.g. pruritus, burning, erythema)
- •9. Allergy to cis-UCA, or any constituents of Aqualan® (decyl oleate, cetearyl alcohol, glycerine, sodium cetearyl sulphate and methylparaben)
- •10. History of any cancer or current cancer
- •11. Earlier participation in a clinical study performed with cis-UCA
- •12. Use of prescription drugs within 14 days prior to dosing or over the counter medication within 7 days prior to dosing. Paracetamol is allowed for occasional pain. Antihistamine is allowed for allergic symptoms. Non-cortisone nasal sprays and eye drops are also allowed.
- •13. Donation of blood or participation in another drug study within 60 days (males) or 90 days (females) before the first product administration in this study
- •14. Any medical condition (such as renal impairment) which might significantly alter the absorption, distribution or excretion of cis-UCA
- •15. Any clinically significant laboratory test result (including positive tests for HIV and hepatitis B or C)
- •16. Excessive use of alcohol (on average more than 24 units per week for males, and more that 16 units per weeks for females; unit = 4 cl spirits or equivalent)
- •17. Suspected current use of illicit drugs (medical history, physical examination, screening laboratory determinations)
- •18. Clinically significant illness during the 4 weeks prior to the first dose administration (as determined by the Investigator)
- •19. Any other condition that in the opinion of the Investigator would interfere with the evaluation of the study results or constitute a health hazard for the subject
- •20. Unwillingness or doubtful capacity to comply with the protocol
- •21. Doubtful availability, in the opinion of the Investigator, to complete the study
- •22. Poor peripheral venous access
研究者
相似试验
招募中
不适用
A Randomized, Double-Blind, Vehicle-Controlled, Phase I Study to Evaluate the Safety and Tolerability of Topically Applied INM-755 Cream on Epidermal Wounds in Healthy Volunteersspontaneaous blistering10014982Epidermolysis BullosaNL-OMON49368InMed Pharmaceuticals Inc.8
已完成
不适用
A Randomized, Double-Blind, Vehicle-Controlled, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Topically Applied INM-755 Cream in Healthy VolunteersEpidermolysis BullosaNL-OMON48156InMed Pharmaceuticals Inc.22
进行中（未招募）
不适用
Double-blind, vehicle-controlled, single centre Phase I/IIa study with topical twice daily doses of 5% cis-urocanic acid to investigate pharmacokinetics, safety, tolerability, and efficacy for up to 28 days in subjects with mild to moderate plaque psoriasisEUCTR2008-008332-90-FIBioCis Pharma Oy18
进行中（未招募）
不适用
A randomised, double-blind, vehicle-controlled, parallel group, multicentre, proof of concept, phase II clinical study to investigate the efficacy and safety of 1 % FR260500 gel in patients with facial acne vulgaris - FR260500 proof of concept acneEUCTR2004-002842-37-GBFujisawa GmbH66
进行中（未招募）
不适用
A randomised, double-blind, vehicle-controlled, parallel group, multicentre, proof of concept, phase II clinical study to investigate the efficacy and safety of 1 % FR260500 gel in patients with facial acne vulgaris - FR260500 proof of concept acneMild to moderate facial acne vulgaris.MedDRA version: 7.0Level: LLTClassification code 10000519EUCTR2004-002842-37-DEFujisawa GmbH66